InvestorsHub Logo
Followers 132
Posts 7805
Boards Moderated 0
Alias Born 12/17/2009

Re: Citrati post# 103

Thursday, 07/27/2017 1:26:23 PM

Thursday, July 27, 2017 1:26:23 PM

Post# of 1509
I think in this space there is ALWAYS the chance for a buyout; i.e. st Jude purchase by Abbott.
Management is younger with NVTR, so likely they are looking to grow the company.
BUT, for the right price I'd bet they'd take a buyout.
I see larger pharmacy getting involved in the stim space to a much greater degree within the next 5-10 years.

Abbott bought St Jude, GSK and Google formed Galvani Bioelectronics (still private and in R&D, but BUY BUY BUY if they ever go public).
Other rumors abound.

It's partially why I'll always hold a core share position.
I feel a good product valuation (not current revenue value, but potential) for NVTR is ranged between 750 million to 2 billion.
With NVTR 10.34 million O/S the math adds up to a VERY nice number.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.